WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
43.67 ^CNY	-2.02%		+1.75%	-39.98%

May. 03	Beijing, Fed Churn Asian Stock Markets in Sparse Trading	MT
Apr. 29	WuXi AppTec Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Megarobo Technology Co., Ltd. announced that it has received $65 million in funding from a group of investors

May 27, 2021

Megarobo Technology Co., Ltd. announced that it has received $65,000,000 in funding led by WuXi AppTec Co., Ltd. on May 28, 2021. The transaction included participation from existing investors, Joy Capital Management, Ltd., Sinovation Ventures (Beijing) Enterprise Management Limited, FutureCap, Robert Bosch Venture Capital GmbH, Jingwei Venture Capital (Beijing) Investment Management Consulting Co., Ltd., and Beijing Liandong Investment (Group) Co., Ltd. .

Latest news about WuXi AppTec Co., Ltd.

Beijing, Fed Churn Asian Stock Markets in Sparse Trading	May. 03	MT
WuXi AppTec Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Full Year 2024	Apr. 29	CI
Interest Rate Outlooks Quell Asian Stock Markets	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Tranche Update on WuXi AppTec Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	Apr. 01	CI
China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators	Mar. 28	RE
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET	Mar. 19	DJ
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET	Mar. 19	DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	Mar. 19	DJ
Nomura Adjusts Wuxi Apptec’s Price Target to 62.75 Yuan From 99.16 Yuan, Keeps at Buy	Mar. 19	MT
Nomura Adjusts Wuxi Apptec’s Price Target to HK$54.56 From HK$86.23, Keeps at Buy	Mar. 19	MT
Hong Kong Shares Slip Amid Downbeat Earnings, Cautious Trade	Mar. 19	MT
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET	Mar. 19	DJ
News Highlights : Top Company News of the Day - Tuesday at 1 AM ET	Mar. 19	DJ
WuXi AppTec's Shares Fall After Downbeat Guidance	Mar. 19	DJ
News Highlights : Top Company News of the Day - Monday at 11 PM ET	Mar. 18	DJ
News Highlights : Top Company News of the Day - Monday at 9 PM ET	Mar. 18	DJ
Wuxi AppTec's 2023 Profit Rises 21% as Revenue Increases	Mar. 18	MT
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat	Mar. 18	DJ
WuXi AppTec Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023	Mar. 18	CI
WuXi AppTec Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Year 2024	Mar. 18	CI
News Highlights : Top Company News of the Day - Friday at 9 AM ET	Mar. 15	DJ

Chart WuXi AppTec Co., Ltd.

Duration

Period

More charts

Company Profile

WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for WuXi AppTec Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

43.67 CNY

Average target price

68.82 CNY

Spread / Average Target

+57.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WUXI APPTEC CO., LTD.	-39.98%	17.08B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
LEGEND BIOTECH CORPORATION	-24.53%	8.26B

Bio Therapeutic Drugs